Clinuvel Pharmaceuticals Limited (CLVLF)
USD 7.45
(0.0%)
USD 7.45
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 88.17 Million AUD | 12.59% |
| 2023 | 78.32 Million AUD | 19.17% |
| 2022 | 65.72 Million AUD | 36.99% |
| 2021 | 47.97 Million AUD | 47.32% |
| 2020 | 32.56 Million AUD | 4.89% |
| 2019 | 31.04 Million AUD | 21.82% |
| 2018 | 25.48 Million AUD | 52.42% |
| 2017 | 16.72 Million AUD | 169.19% |
| 2016 | 6.21 Million AUD | 113.33% |
| 2015 | 2.91 Million AUD | 32.34% |
| 2014 | 2.2 Million AUD | 41.67% |
| 2013 | 1.55 Million AUD | 114.86% |
| 2012 | 722.8 Thousand AUD | -30.57% |
| 2011 | 1.04 Million AUD | 0.0% |
| 2010 | - AUD | 0.0% |
| 2009 | - AUD | 0.0% |
| 2008 | - AUD | -100.0% |
| 2007 | 283.3 Thousand AUD | -62.47% |
| 2006 | 754.84 Thousand AUD | 505.71% |
| 2005 | 124.62 Thousand AUD | 0.0% |
| 2004 | - AUD | 0.0% |
| 2003 | - AUD | 0.0% |
| 2002 | - AUD | 0.0% |
| 2001 | - AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q4 | 55.92 Million AUD | 0.0% |
| 2024 FY | 88.17 Million AUD | 12.59% |
| 2024 Q1 | 16.4 Million AUD | -66.51% |
| 2024 Q2 | 32.25 Million AUD | 96.68% |
| 2023 Q2 | 29.35 Million AUD | 99.92% |
| 2023 FY | 78.32 Million AUD | 19.17% |
| 2023 Q1 | 14.68 Million AUD | -64.27% |
| 2023 Q3 | 24.47 Million AUD | -16.62% |
| 2023 Q4 | 48.96 Million AUD | 100.05% |
| 2022 Q1 | 12.42 Million AUD | -61.47% |
| 2022 FY | 65.72 Million AUD | 36.99% |
| 2022 Q4 | 41.09 Million AUD | 101.03% |
| 2022 Q3 | 20.44 Million AUD | -17.01% |
| 2022 Q2 | 24.63 Million AUD | 98.31% |
| 2021 Q2 | 15.74 Million AUD | 100.0% |
| 2021 Q4 | 32.23 Million AUD | 97.9% |
| 2021 Q3 | 16.28 Million AUD | 3.46% |
| 2021 Q1 | 7.87 Million AUD | -65.16% |
| 2021 FY | 47.97 Million AUD | 47.32% |
| 2020 Q4 | 22.59 Million AUD | 100.0% |
| 2020 FY | 32.56 Million AUD | 4.89% |
| 2020 Q1 | 4.98 Million AUD | -77.41% |
| 2020 Q2 | 9.97 Million AUD | 100.0% |
| 2020 Q3 | 11.29 Million AUD | 13.3% |
| 2019 Q2 | 4.49 Million AUD | 0.0% |
| 2019 Q3 | 11.03 Million AUD | 145.69% |
| 2019 FY | 31.04 Million AUD | 21.82% |
| 2019 Q1 | 4.49 Million AUD | -51.23% |
| 2019 Q4 | 22.06 Million AUD | 100.0% |
| 2018 Q3 | 9.2 Million AUD | 160.49% |
| 2018 Q4 | 9.2 Million AUD | 0.0% |
| 2018 Q2 | 3.53 Million AUD | -0.0% |
| 2018 FY | 25.48 Million AUD | 52.42% |
| 2018 Q1 | 3.53 Million AUD | -28.42% |
| 2017 Q2 | 3.44 Million AUD | 0.0% |
| 2017 Q1 | 3.44 Million AUD | 32.71% |
| 2017 Q4 | 4.93 Million AUD | 0.0% |
| 2017 FY | 16.72 Million AUD | 169.19% |
| 2017 Q3 | 4.93 Million AUD | 43.39% |
| 2016 Q1 | 815.02 Thousand AUD | -27.41% |
| 2016 FY | 6.21 Million AUD | 113.33% |
| 2016 Q4 | 2.59 Million AUD | 0.0% |
| 2016 Q3 | 2.59 Million AUD | 218.42% |
| 2016 Q2 | 815.02 Thousand AUD | -0.0% |
| 2015 Q2 | 536.1 Thousand AUD | 0.0% |
| 2015 Q3 | 1.12 Million AUD | 109.42% |
| 2015 FY | 2.91 Million AUD | 32.34% |
| 2015 Q4 | 1.12 Million AUD | 0.0% |
| 2015 Q1 | 536.1 Thousand AUD | -40.98% |
| 2014 FY | 2.2 Million AUD | 41.67% |
| 2014 Q4 | 908.3 Thousand AUD | 0.0% |
| 2014 Q1 | 423.25 Thousand AUD | -43.6% |
| 2014 Q2 | 423.25 Thousand AUD | -0.0% |
| 2014 Q3 | 908.3 Thousand AUD | 114.6% |
| 2013 FY | 1.55 Million AUD | 114.86% |
| 2013 Q3 | 750.5 Thousand AUD | 0.0% |
| 2013 Q4 | 750.5 Thousand AUD | 0.0% |
| 2012 FY | 722.8 Thousand AUD | -30.57% |
| 2011 FY | 1.04 Million AUD | 0.0% |
| 2010 FY | - AUD | 0.0% |
| 2009 FY | - AUD | 0.0% |
| 2008 FY | - AUD | -100.0% |
| 2007 FY | 283.3 Thousand AUD | -62.47% |
| 2006 FY | 754.84 Thousand AUD | 505.71% |
| 2005 FY | 124.62 Thousand AUD | 0.0% |
| 2004 FY | - AUD | 0.0% |
| 2003 FY | - AUD | 0.0% |
| 2002 FY | - AUD | 0.0% |
| 2001 FY | - AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 18.21 Million USD | -384.017% |
| BioStem Technologies, Inc. | 16.68 Million USD | -428.476% |
| Santhera Pharmaceuticals Holding AG | 122.95 Million USD | 28.283% |
| Northwest Biotherapeutics, Inc. | 1.93 Million USD | -4464.095% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -37175.24% |
| Acro Biomedical Co., Ltd. | 658.5 Thousand USD | -13290.783% |
| Arch Therapeutics, Inc. | 75.72 Thousand USD | -116346.976% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Skye Bioscience, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| CSL Limited | 14.69 Billion USD | 99.4% |
| Capstone Therapeutics Corp. | 48.35 Million USD | -82.36% |
| Adynxx, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 15.77 Million USD | -459.046% |
| Nanobac Pharmaceuticals, Incorporated | 17.62 Thousand USD | -500316.026% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 21.47 Million USD | -310.552% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -134056.384% |
| Propanc Biopharma, Inc. | - USD | -Infinity% |
| Mesoblast Limited | 5.9 Million USD | -1394.041% |
| Marizyme, Inc. | 645.81 Thousand USD | -13553.909% |
| Genus plc | 668.8 Million USD | 86.815% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 245.31 Million USD | 64.055% |
| Therapeutic Solutions International, Inc. | 98.99 Thousand USD | -88974.396% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -21398.253% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -114773.84% |
| IMV Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 39.51 Thousand USD | -223034.541% |
| MultiCell Technologies, Inc. | 49.32 USD | -178788034.631% |
| ONE Bio Corp. | 52.29 Million USD | -68.613% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 49.72 Million USD | -77.346% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -180223.738% |
| Q BioMed Inc. | 284.35 Thousand USD | -30910.265% |
| Emmaus Life Sciences, Inc. | 29.59 Million USD | -197.93% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 145.09 Million USD | 39.229% |
| Provectus Biopharmaceuticals, Inc. | 557.71 Thousand USD | -15710.781% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -125869.011% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 999.00 USD | -8826557.457% |
| Enzolytics Inc. | 52.79 Thousand USD | -166917.024% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 608.52 Thousand USD | -14390.499% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.22 Billion USD | 92.809% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 140.24 Thousand USD | -62775.82% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -14182.571% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 839.52 Million USD | 89.497% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Kadimastem Ltd | - USD | -Infinity% |
| Helix BioMedix, Inc. | 997.72 Thousand USD | -8737.928% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -37175.24% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.36 Million USD | -6341.074% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | - USD | -Infinity% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 473.73 Thousand USD | -18513.621% |
| SYBLEU INC | 11.69 Thousand USD | -753818.502% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 7.78 Million USD | -1032.088% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 13 Thousand USD | -678194.677% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | - USD | -Infinity% |
| Neutra Corp. | 39.53 Thousand USD | -222944.235% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| PureTech Health plc | 3.33 Million USD | -2547.997% |
| Coeptis Therapeutics, Inc. | - USD | -Infinity% |
| IXICO plc | 6.66 Million USD | -1223.005% |
| IntelGenx Technologies Corp. | 1.03 Million USD | -8386.844% |
| Gelesis Holdings, Inc. | 25.76 Million USD | -242.214% |
| CSL Limited | 14.8 Billion USD | 99.404% |
| Cellectis S.A. | 755 Thousand USD | -11579.246% |